Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics (KPTI) Tops Q4 EPS by 95c

February 8, 2022 7:37 AM EST

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of $0.46, $0.95 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $126.3 million versus the consensus estimate of $50.49 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

... More